Management of muscle haematomas in patients with severe haemophilia in an evidence-poor world

Haemophilia

Volumn 18, Issue 4, 2012, Pages 598-606

  Sorensen B ^a,b   Benson, G M ^c   Bladen, M ^d   Classey, S ^a   Keeling, D M ^e   Mclaughlin, P ^f   Yee, T T ^f   Makris, M ^g  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c BELFAST CITY HOSPITAL   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e CHURCHILL HOSPITAL   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

^g ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Haemophilia; Muscle haematoma; Physiotherapy; Rehabilitation

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTHROMBIN COMPLEX; NONSTEROID ANTIINFLAMMATORY AGENT; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

BLEEDING; BLEEDING TIME; BOVINE DIARRHEA VIRUS; CONTRACTURE; DISEASE SEVERITY; FLEXOR MUSCLE; HEMOPHILIA; HUMAN; ILIOPSOAS MUSCLE; MEDICAL EDUCATION; MEDICAL HISTORY; MUSCLE HEMATOMA; PATIENT EDUCATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PHYSIOTHERAPY; PRIORITY JOURNAL; RANGE OF MOTION; REHABILITATION; REVIEW; SPORT; THROMBOCYTE AGGREGATION; TREATMENT DURATION;

ATHLETIC INJURIES; BLOOD COAGULATION FACTORS; COAGULANTS; EVIDENCE-BASED MEDICINE; HEMATOMA; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MUSCULAR DISEASES; PHYSICAL THERAPY MODALITIES;

EID: 84863216759     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02720.x     Document Type: Review

References (59)

1. Beyer R, Ingerslev J, Sørensen B. Current practice in the management of muscle haematomas in patients with severe haemophilia. Haemophilia 2010; 16: 926-31.
2. Beyer R, Ingerslev J, Sørensen B. Muscle bleeds in professional athletes - diagnosis, classification, treatment and potential impact in patients with haemophilia. Haemophilia 2010; 16: 858-65.
3. Alcalay M, Deplas A. Rheumatological management of patients with hemophilia. Part II: muscle hematomas and pseudotumours. Joint Bone Spine 2002; 69: 556-9.
4. Balkan C, Kavakli K, Karapinar D. Iliopsoas haemorrhage in patients with haemophilia: results of one centre. Haemophilia 2005; 11: 463-7.
5. Al Saadi AS, Al Wadan AH, El Hamarneh SA, Emad ME. Life-threatening biopsy of an iliopsoas pseudotumour in a patient with haemophilia: a case report. J Med Case Reports 2008; 2: 135.
6. Rodriguez-Merchan EC. Musculoskeletal complications of haemophilia. HSS J 2010; 6: 37-42.
7. Mason DL, Dickens V, Vail A. Rehabilitation for hamstring injuries. Cochrane Database Syst Rev 2007; 2: CD004575.
8. Blamey G, Forsyth A, Zourikian N et al. Comprehensive elements of a physiotherapy exercise programme in haemophilia: a global perspective. Haemophilia 2010; 16: 136-45.
9. Pope RP, Herbert RD, Kirwan JD, Graham BJ. A randomized trial of preexercise stretching for prevention of lower-limb injury. Med Sci Sports Exerc 2000; 32: 271-7.
10. Herbert RD, Gabriel M. Effects of stretching before and after exercising on muscle soreness and risk of injury: systematic review. BMJ 2002; 325: 468.
11. Broderick CR, Herbert RD, Latimer J, Curtin JA. Fitness and quality of life in children with haemophilia. Haemophilia 2010; 16: 118-23.
12. Falk B, Portal S, Tiktinsky R et al. Bone properties and muscle strength of young haemophilia patients. Haemophilia 2005; 11: 380-6.
13. González LM, Querol F, Gallach JE, Gomis M, Aznar VA. Force fluctuations during the maximum isometric voluntary contraction of the quadriceps femoris in haemophilic patients. Haemophilia 2007; 13: 65-70.
14. Lusher JM. Early treatment with recombinant factor VIIa results in greater efficacy with less product. Eur J Haematol Suppl 1998; 63: 7-10.
15. Salek SZ, Benson GM, Elezović I et al. The need for speed in the management of haemophilia patients with inhibitors. Haemophilia 2011; 17: 95-102.
16. Schwellnus MP. A clinical approach to the diagnosis and management of acute muscle injuries in sport. Int SportMed J 2004; 5: 188-99.
17. Mahlangu JN, Gilham A. Medical and Scientific Advisory Council of the South African Haemophilia Foundation. Guideline for the treatment of haemophilia in South Africa. S Afr Med J 2008; 98: 126-40.
18. Smith TO, Hunt NJ, Wood SJ. The physiotherapy management of muscle haematomas. Phys Ther Sport 2006; 7: 201-9.
19. White GC 2nd, Courter S, Bray GL, Lee M, Gomperts ED. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group. Thromb Haemost 1997; 77: 660-7.
20. Roth DA, Kessler CM, Pasi KJ et al. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 2001; 98: 3600-6.
21. Shapiro AD, Di Paola J, Cohen A et al. The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B. Blood 2005; 105: 518-25.
22. Ashrani AA, Osip J, Christie B, Key NS. Iliopsoas haemorrhage in patients with bleeding disorders - experience from one centre. Haemophilia 2003; 9: 721-6.
23. World Federation of Hemophilia. Guidelines for the management of hemophilia. Available at. Accessed November 28, 2010.
24. Berntorp E, Collins P, d'Oiron R et al. Identifying non-responsive bleeding episodes in patients with haemophilia and inhibitors: a consensus definition. Haemophilia 2011; 17: 202-10.
25. Abebe W. Herbal medication: potential for interactions with analgesic drugs. J Clin Pharm Ther 2002; 27: 391-401.
26. Rattray B, Nugent DJ, Young G. Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophilia. Haemophilia 2006; 12: 514-7.
27. Rattray B, Nugent DJ, Young G. Rofecoxib as adjunctive therapy for haemophilic arthropathy. Haemophilia 2005; 11: 240-4.
28. Hoffman M, Monroe DM. Wound healing in haemophilia - breaking the vicious cycle. Haemophilia 2010; 16 (Suppl. 3): 13-8.
29. Smejkal P, Brabec P, Matyskova M et al. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia 2009; 15: 743-51.
30. Hvas AM, Sørensen HT, Norengaard L, Christiansen K, Ingerslev J, Sørensen B. Tranexamic acid combined with recombinant factor VIII increases clot resistance to accelerated fibrinolysis in severe hemophilia A. J Thromb Haemost 2007; 5: 2408-14.
31. Arkin S, Blei F, Fetten J et al. Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitors. Blood Coagul Fibrinolysis 2000; 11: 255-9.
32. Salaj P, Brabec P, Penka M et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia 2009; 15: 752-9.
33. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Register. Haemophilia 2005; 11: 100-6.
34. Young G, Shapiro AD, Valentino LA, Kessler CM, Cooper DL. Diary observational study in hemophilia (DOSE): evaluation of enrolled population and overall diary capture in congenital hemophilia patients with alloantibody inhibitors. Blood 2009; 114: 1352-3.
35. Gringeri A, Fischer K, Karafoulidou A et al. Sequential combined bypassing therapy (SCBT) is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors. Haemophilia 2011; 17: 630-5.
36. Teitel J, Berntorp E, Collins P et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007; 13: 256-63.
37. Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007; 13: 244-8.
38. Martinowitz U, Livnat T, Zivelin A, Kenet G. Concomitant infusion of low doses of rFVIIa and FEIBA in haemophilia patients with inhibitors. Haemophilia 2009; 15: 904-10.
39. FEIBA. International Summary of Product Characteristics 2009. Available at. Accessed March 3, 2011.
40. NovoSeven Summary of Product Characteristics 2010. Available at. Accessed December 16, 2010.
41. FDA. Risk of thrombotic and thromboembolic events following infusion of FEIBA VH or FEIBA NF, particularly following the administration of high doses and/or in patients with thrombotic risk factors. Available at. Accessed January 6, 2011.
42. Lisman T, Mosnier LO, Lambert T et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A. Blood 2002; 99: 175-9.
43. Peterson L, Renström P. Sports Injuries: Their Prevention and Treatment, 3rd edn. London: Martin Dunitz, 2001.
44. Renström P. Muscle injuries. In: Ekstrand J, Karlsson J, Hodson A eds. Football Medicine. London: Martin Dunitz, 2003: 217-8.
45. Holme PA, Glomstein A, Gronhaug S, Tjonnfjord GE. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience. Haemophilia 2009; 15: 727-32.
46. Algafly AA, George KP. The effect of cryotherapy on nerve conduction velocity, pain threshold and pain tolerance. Br J Sports Med 2007; 41: 365-9.
47. Thorsson O, Hemdal B, Lilja B, Westlin N. The effect of external pressure on intra-muscular blood flow at rest and after running. Scand J Med Sci Sports 1987; 19: 469-73.
48. Thorsson O, Hemdal B, Lilja B, Westlin N. Immediate external compression in the management of an acute muscle injury. Scand J Med Sci Sports 1997; 7: 182-90.
49. Williams JGP. Muscle haematomas. Physiotherapy 1980; 66: 212-4.
50. Rizzo BL. Rehabilitation in haemophilia - options in the developing world. Haemophilia 1998; 4: 486-90.
51. Takala TE, Virtanen P. Biochemical composition of muscle extracellular matrix: the effect of loading. Scand J Med Sci Sports 2000; 10: 321-5.
52. Kääriäinen M, Järvinen T, Järvinen M, Rantanen J, Kalimo H. Relationship between myofibers and connective tissue during muscle injury repair. Scand J Med Sci Sports 2000; 10: 332-7.
53. Huard L, Li Y, Fu FH. Muscle injuries and repair: current trends in research. J Bone Joint Surg Am 2002; 84-A: 822-32.
54. Mulder K. Exercises for People with Hemophilia. Montreal: World Federation of Hemophilia, 2006.
55. Heijnen L. The role of rehabilitation and sports in haemophilia patients with inhibitors. Haemophilia 2008; 14 (Suppl. 6): 45-51.
56. Young SR, Dyson M. The effect of therapeutic ultrasound on angiogenesis. Ultrasound Med Biol 1990; 16: 261-9.
57. Reed A, Low J. Electrotherapy Explained: Principles and Practice, 3rd edn. London: Butterworth-Heinemann, 1999.
58. Giombini A, Casciello G, Di Cesare MC, DiCesare A, Dragoni S, Sorrenti D. A controlled study on the effects of hyperthermia at 434MHz and conventional ultrasound upon muscle injuries in sport. J Sports Med Phys Fitness 2001; 41: 521-7.
59. Merli P. Rehabilitation of musculoskeletal system lesions in hemophilic patients. Gazz Med Ital 2002; 161: 69-75.